drugset / Trial / NCT01694667

Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder

NCT01694667

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The proposed study is an internet-based, randomized, double-blind, placebo-controlled trial which will assess changes in hyperactivity in children ages five through eight with an autism spectrum disorders (ASD) and elevated levels of hyperactivity. In order to answer this question, this study will assess changes in hyperactivity as measured by the Aberrant Behavior Checklist (ABC) in children with ASD and elevated baseline levels of hyperactivity who are randomly assigned to use 1.3 grams of omega-3 fatty acids daily compared to placebo. The overwhelming majority of study procedures, including recruitment, informed consent, assessment of inclusion and exclusion criteria, and collection of baseline and outcome measures will take place over the internet.

Timeline

Start
2012-09
Primary completion
2012-12
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Omega-3 fatty acids Unknown 650 mg